Filing Flows › Xeris Biopharma Holdings (XERS) › How it makes money
How Xeris Biopharma Holdings (XERS) makes money
Xeris Biopharma Holdings (XERS) made $107M of revenue in the third quarter 2026 (Q3 2026), +44% from a year earlier. Product revenue, net brought in $106M (99%); Royalty, contract and other revenue brought in $958K (1%). Of every dollar of revenue, 16¢ was left as operating profit, 11¢ was left as net earnings.
Drawing the Sankey…
Revenue by segment, Q3 2026
| Segment | Revenue | Share | Q/Q | Y/Y |
|---|---|---|---|---|
| Product revenue, net | $106M | 99.1% | +17% | +43% |
| ↳ Recorlev | $71.5M | 66.7% | +26% | +93% |
| ↳ Gvoke | $21.7M | 20.2% | -4% | -14% |
| ↳ Keveyis | $13.0M | 12.1% | +12% | +9% |
| Royalty, contract and other revenue | $958K | 0.9% | -13% | +202% |
Where each dollar of revenue goes
| Line | Q3 2026 | % of revenue |
|---|---|---|
| Revenue | $107M | 100.0% |
| Operating profit | $16.9M | 15.8% |
| Net earnings | $11.3M | 10.5% |
| Operating cash flow | $35.5M | 33.1% |
Revenue, quarter by quarter
| Quarter | Revenue | Y/Y |
|---|---|---|
| Q3 2026 | $107M | +44% |
| Q2 2026 | $92.1M | +29% |
| Q1 2026 | $83.1M | +38% |
| Q4 2025 | $85.8M | +43% |
| Q3 2025 | $74.4M | +37% |
| Q2 2025 | $71.5M | +49% |
| Q1 2025 | $60.1M | +48% |
From Xeris Biopharma Holdings' 10-Q filed Nov 5, 2026 (on EDGAR).
Questions
How does Xeris Biopharma Holdings make money?
Xeris Biopharma Holdings (XERS) made $107M of revenue in the third quarter 2026 (Q3 2026), +44% from a year earlier. Product revenue, net brought in $106M (99%); Royalty, contract and other revenue brought in $958K (1%). Of every dollar of revenue, 16¢ was left as operating profit, 11¢ was left as net earnings.
What is Xeris Biopharma Holdings' biggest business?
Product revenue, net: $106M in the third quarter 2026, 99% of revenue, +43% from a year earlier.
What is Xeris Biopharma Holdings' profit margin?
Net earnings were $11.3M, 10.5% of revenue, in the third quarter 2026; the operating margin was 15.8%.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.